Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer
The Breast · 2023-04 · 68 · 173-180
DOI: 10.1016/j.breast.2023.02.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Breast, 2023-04. Verfasst von Yitian Lang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Huangpu Branch, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, No.58 Puyu East Road, Hua…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Wu Jieping Medical Foundation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: The ASCENT trial demonstrated the efficacy of sacituzumab govitecan for the treatment of advanced or metastatic triple-negative breast cancer (TNBC). The current study evaluated the cost-effectiveness of receiving sacituzumab govitecan compared with standard of care chemotherapy from the United States payer perspective. METHODS: A partitioned survival approach was used to project the disease course of advanced or metastatic TNBC. Two survival modes were applied to analyze two groups of patients. The survival data were gathered from the ASCENT trial. Direct medical costs were derived from the data of Centers for Medicare & Medicaid Services. Utility data was collected from the published literature. The incremental cost-utility ratio (ICUR) was the primary outcome that measured the cost-effectiveness of therapy regimen. One-way sensitivity and probabilistic sensitivity analysis were implemented to explore the uncertainty and validate the stability of results. RESULTS: In the base-case, the ICUR of sacituzumab govitecan versus chemotherapy is $ 778,771.9/QALY and $ 702,281/QALY for full population group and brain metastatic-negative (BMN) group with the setting of classic survival mode. And in the setting of cure survival mode, the ICUR is $ 506,504.5/QALY for the full population group and $ 274,232.0/QALY for BMN population group. One-way sensitivity analyses revealed that the unit cost of sacituzumab govitecan and body weight were key roles that lower the ICUR value. Probabilistic sensitivity analyses also showed that reducing the unit price of sacituzumab govitecan can improve the likelihood of becoming cost-effective. CONCLUSION: The cost-effectiveness analysis suggested that from a US payer perspective, sacituzumab govitecan at current price is unlikely to be a preferred option for patients with advanced or metastatic TNBC at a threshold of $ 150,000/QALY.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Huangpu Branch, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, No.58 Puyu East Road, Huangpu District, Shanghai, 200011, China.
- Department of Pharmacy, Huangpu Branch, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, No.58 Puyu East Road, Huangpu District, Shanghai, 200011, China. Electronic address: liuxiaoyan…
- Medical Decision and Economic Group, Department of Pharmacy, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University, No.2000 Jiangyue Road, Minhang District, Shanghai, 201100, China. Electronic…
Förderung
- Wu Jieping Medical Foundation
Zitieren
APA
Lang, Y., Chai, Q., Tao, W., Liao, Y., Liu, X., & Wu, B. (2023). Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer. The Breast, 68, 173-180. https://doi.org/10.1016/j.breast.2023.02.003
Vancouver
Lang Y, Chai Q, Tao W, Liao Y, Liu X, Wu B. Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer. The Breast. 2023;68:173-180. doi:10.1016/j.breast.2023.02.003
BibTeX
@article{Lang2023,
author = {Lang, Yitian and Chai, Qingqing and Tao, Wenqi and Liao, Yahui and Liu, Xiaoyan and Wu, Bin},
title = {Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer},
journal = {The Breast},
year = {2023},
volume = {68},
pages = {173--180},
doi = {10.1016/j.breast.2023.02.003}
}
EUVIMED